Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

November 3, 2020

Study Completion Date

July 19, 2023

Conditions
Severe Aplastic Anemia
Interventions
DRUG

cyclosporine

cyclosporine

PROCEDURE

Matched Unrelated Donor Hematopoietic Stem Cell Transplant

Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)

DRUG

horse anti-thymocyte globulin (ATG)

horse anti-thymocyte globulin (ATG)

DRUG

rabbit anti-thymocyte globulin (ATG)

rabbit anti-thymocyte globulin (ATG)

DRUG

methotrexate

methotrexate

DRUG

fludarabine

fludarabine

DRUG

cyclophosphamide

cyclophosphamide

RADIATION

low-dose total body irradiation (TBI)

low-dose total body irradiation (TBI)

PROCEDURE

Immunosuppressive Therapy (IST)

Immunosuppressive Therapy (IST)

Trial Locations (13)

11040

Cohen Children's Medical Center, Queens

19104

Children's Hospital of Philadelphia, Philadelphia

44195

Cleveland Clinic, Cleveland

53792

University of Wisconsin, Madison

75390

UT Southwestern Medical Center, Dallas

77030

Texas Children's Hospital, Houston

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

94123

UCSF, San Francisco

94304

Stanford Lucile Packard Children's Hospital, Palo Alto

98109

Fred Hutchinson Cancer Research Center, Seattle

02115

Boston Children's Hospital, Boston

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Michael Pulsipher

OTHER

NCT02845596 - Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia | Biotech Hunter | Biotech Hunter